Autolus director granted options and RSUs
Autolus Therapeutics plc director Michael W. Bonney received new equity-based compensation.
Rhea-AI Filing Summary
Autolus Therapeutics plc director Michael W. Bonney received new equity-based compensation. He was granted options to buy 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026.
He also received 31,667 restricted share units, each representing one American Depositary Share, which vest in a single installment on June 29, 2027. These awards increase his potential future ownership but are subject to time-based vesting.
Positive
- None.
Negative
- None.
Insights
Director receives routine option and RSU grants with future vesting.
Director Michael W. Bonney was granted 47,500 share options with a $1.61 exercise price and 31,667 RSUs, all tied to Autolus Therapeutics plc American Depositary Shares. Both awards are classified as grant or award acquisitions, not market purchases.
The RSUs vest on June 29, 2027, while the options vest monthly over twelve installments starting July 29, 2026 and expire on June 29, 2036. These time-based schedules align the director’s potential equity value with longer-term service.
Since there are no open-market buys or sells and no remaining derivative positions listed, this filing reflects a standard equity compensation event rather than a signaling trade. Future company filings may show when these awards vest or are exercised.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Units | 31,667 | $0.00 | $0.00 |
| Grant/Award | Share Option (Right to Buy) | 47,500 | $0.00 | $0.00 |
Footnotes (3)
- F1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
- F2. The RSUs vest in one installment on June 29, 2027.
- F3. Share options vest in twelve equal monthly installments commencing on July 29, 2026.
Key Figures
Key Terms
transaction code A financial
FAQ
What did Autolus Therapeutics (AUTL) director Michael Bonney receive in this Form 4?
Are the Autolus Therapeutics (AUTL) transactions in this Form 4 insider buys or sells?
What are the details of Michael Bonney’s stock option grant at Autolus Therapeutics (AUTL)?
How do the Autolus Therapeutics (AUTL) RSUs granted to Michael Bonney vest?
Does this Autolus Therapeutics (AUTL) Form 4 indicate remaining derivative positions after the grants?
AI-generated analysis. How Rhea-AI works. Not financial advice.